Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp (NQ: LEXX )

3.220 +0.220 (+7.34%)
Streaming Delayed Price Updated: 1:55 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp

< Previous 1 2
...
19 20 21 22 23 24 25 26 Next >
Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19 Product Safety
Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)
New York, New York--(Newsfile Corp. - June 17, 2021) - PCG Digital -- Lexaria Bioscience Corp. (NASDAQ: LEXX) hit a... 
Via Newsfile
Exposures COVID-19 Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Clearside Biomedical (NASDAQ:CLSD) stock increased by 50.99% to $4.56 during Tuesday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs
DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2 KELOWNA, BC / ACCESSWIRE / June 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Lexaria Provides Progress Report on Six R&D Programs
- All studies are using DehydraTECH™ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine - These studies are part of Lexaria's 2021 applied... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Animal Testing Intellectual Property
Exposures Animal Testing COVID-19 Intellectual Property
Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1
- Dosing Is Complete in First of Three Human Clinical Studies Hoped To Validate Lexaria’s Patented Technology for Hypertension Relief - Study Tested an Advanced “DehydraTECH™ 2.0” CBD Formulation -... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Lexaria Bioscience on Drug Delivery Technology and its Patented DehydraTECH
Lexaria Bioscience Corp. (NASDAQ: LEXX) Chairman and CEO Chris Bunka began the Benzinga Global Small Cap Business Conference presentation on May 13, 2021, by clarifying a few key... 
Via Benzinga
Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus
KELOWNA, BC / ACCESSWIRE / June 3, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Lexaria's DehydraTECHTM Drug Delivery Technology Is Investigating Applications in Multiple Markets Valued Over USD $100 Billion
Developing a safe and effective drug is important, but it’s only part of the picture. For the therapeutic effect of a drug to be effective, it largely depends on the... 
Via Benzinga
VIDEO: Benzinga Cannabis Hour | Nasdaq Edition Ft. The Alkaline Water Company And Lexaria Bioscience
Benzinga Cannabis Hour is a weekly show that focuses on the latest news and business trends in the cannabis industry. So, let... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers VistaGen Therapeutics (NASDAQ:VTGN) shares moved upwards by 14.34% to $2.63 during Thursday's pre-market session. The market value of their outstanding shares... 
Via Benzinga
Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever
- New formulation delivers up to 2,708% more CBD into bloodstream* - Human clinical hypertension study HYPER-H21-1 also progressing KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp.... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Animal Testing Intellectual Property
Exposures Animal Testing Intellectual Property
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Second Sight Medical (NASDAQ:EYES) shares increased by 25.39% to $6.27 during Wednesday's pre-market session. The company's market cap stands at $174.9... 
Via Benzinga
Lexaria Strengthens Its International Patent Portfolio to 19 Patents Granted
- New patent granted in India bolsters worldwide patent coverage, adding to existing patents in the EU, the U.S., and Australia KELOWNA, BC / ACCESSWIRE / May 12, 2021 / Lexaria Bioscience Corp.... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. Discusses Potential of DehydraTECH(TM) CBD for Revolutionary Hypertension Solution with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - May 7, 2021) - The Stock Day Podcast welcomed Lexaria Bioscience Corp. (NASDAQ: LEXX) ("the Company"),... 
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
Lexaria to Present at the Benzinga Global Small Cap Conference on May 13, 2021 at 3:50 p.m. ET
Lexaria Recently Announced Favorable Data on Its First Animal Study, As Well as the Commencement of Its First Human Clinical Study, Under Its 2021 Hypertension R&D Program KELOWNA, BC / ACCESSWIRE /... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
32 Stocks Moving in Friday's Pre-Market Session
Gainers Assertio Holdings, Inc. (NASDAQ: ASRT) shares rose 44.2% to $0.7190 in pre-market trading after the company reported better-than-expected Q1 results. iBio, Inc. (NYSE:... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Lexaria Bioscience (NASDAQ:LEXX) shares rose 53.87% to $7.74 during Thursday's regular session. As of 12:30 EST, Lexaria Bioscience's stock is trading at a... 
Via Benzinga
Mid-Morning Market Update: Markets Mostly Lower; Kellogg Earnings Beat Views
Following the market opening Thursday, the Dow traded down 0.03% to 34,218.62 while the NASDAQ fell 0.70% to 13,487.34. The S&P also fell, dropping 0.31% to 4,154.86. The U.S... 
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
72 Biggest Movers From Yesterday
Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares surged 85.8% to settle at $10.22 on above-average volume. Liquidity Services, Inc. (NASDAQ: LQDT) jumped 37.7% to settle at $25... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Stealth BioTherapeutics (NASDAQ:MITO) stock moved upwards by 58.33% to $1.9 during Thursday's pre-market session. The market value of their outstanding shares... 
Via Benzinga
58 Stocks Moving In Thursday's Mid-Day Session
Gainers Stealth BioTherapeutics Corp (NASDAQ: MITO) shares surged 92.9% to $2.3150. Stealth BioTherapeutics presented at the Association for Research in Vision and Ophthalmology... 
Via Benzinga
Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1
- Up to 2,178% more CBD delivered into bloodstream* - Up to 1,737% more CBD delivered into brain tissue* KELOWNA, BC / ACCESSWIRE / May 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW)... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
BTV Explores Investment Options in Life Sciences
Vancouver, British Columbia--(Newsfile Corp. - May 6, 2021) - On national TV Sat. May 8 & Sun. May 9, 2021... 
Via Newsfile
Exposures COVID-19
Lexaria Bioscience Corp., Proprietary Drug Delivery Technology, CEO Clip Video
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2021) - Lexaria Bioscience Corp. (CSE: LXX) (NASDAQ: LEXX) - Chris Bunka,... 
Via Newsfile
Lexaria Commences Human Clinical Hypertension Study
- Study to examine DehydraTECHTM CBD's ability to control blood pressure - First of three human clinical studies hoped to validate Lexaria's patented technology for hypertension relief KELOWNA, BC /... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Ardelyx, Inc. (NASDAQ:... 
Via Benzinga
The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) Alexion Pharmaceuticals,... 
Via Benzinga
Lexaria Appoints New Chief Financial Officer and Issues Consultant Warrants
KELOWNA, BC / ACCESSWIRE / April 15, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria's DehydraTECHTM Technology Utilized in Amari's "Everyday Calm," Named a Top CBD Product Pick by New Hope Network
- DehydraTECHTM Powers Amari's Award-Winning Products KELOWNA, BC / ACCESSWIRE / April 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property Supply Chain
Exposures Intellectual Property Supply Chain
< Previous 1 2
...
19 20 21 22 23 24 25 26 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.